Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Breast Neoplasms 7Waldenstrom Macroglobulinemia 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Triple Negative Breast Neoplasms 2Rectal Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Anaplastic 2Leukemia, Lymphocytic, Chronic, B-Cell 2Intraocular Lymphoma 2Hodgkin Disease 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms, Male 2Unspecified Childhood Solid Tumor, Protocol Specific 1Thromboembolism 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Abnormalities 1Sezary Syndrome 1Salivary Gland Neoplasms 1Radiation Injuries 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Carboplatin 44Paclitaxel 41Cyclophosphamide 21Topotecan 19Cisplatin 18Peripheral Blood Stem Cell Transplantation 15Filgrastim 15Docetaxel 15Gemcitabine 13Bevacizumab 13liposomal doxorubicin 11Hyperthermic Intraperitoneal Chemotherapy 11sargramostim 9Therapeutics 8Immunohistochemistry 8Psychiatric Rehabilitation 7Drug Therapy 7Amifostine 7pembrolizumab 6olaparib 6Taxes 6Surveys and Questionnaires 6Melphalan 6Flow Cytometry 6Early Intervention, Educational 6Chemotherapy, Adjuvant 6niraparib 5denileukin diftitox 5Surgical Procedures, Operative 5Immunoenzyme Techniques 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Ovarian Epithelial × Enzyme-Linked Immunosorbent Assay × Clear all
NCT01673217 2022-08-01

Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Roswell Park Cancer Institute

Phase 1 Completed
18 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT00357448 2019-05-14

Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer

University of Washington

Phase 1 Completed
11 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡